A vaccine clinical research center has been opened by PPD, Inc., in Taizhou, China, one of the country's major regions for conducting vaccine studies.
PPD will provide clinical monitoring services through the center to both local and global biopharmaceutical companies seeking to develop vaccines within China.
The newly opened center, which is located at the Taizhou China Medical City, will aid biopharmaceutical companies in addressing the unique requirements of conducting vaccine clinical trials in the country.
The Chinese Center for Disease Control and Prevention conducts vaccine studies in China instead of Phase I clinics or investigators at hospitals. Thousands of patients are required for enrollment compared to the hundreds required for studies in other countries.
China, however, only offers a short recruitment period for vaccine trials.
"The vaccines market is one of the fastest growing segments in the industry, and in China the clinical trial market is growing at about 20 percent each year," Simon Britton, PPD's vice president of clinical development for Asia Pacific, said. "Our strong expertise in vaccine clinical research and large presence in China make us well positioned to help our clients ensure adherence to global standards while addressing unique requirements for monitoring vaccine studies."
In recent years, the China Medical City has made a name for itself as a national hub for international and domestic pharmaceutical, biomedical and biotechnology companies. It is part of a long term plan meant to advance Taizhou as a global leader in research and development and to position it as one of the world's premier biopharmaceutical facilities.